Search Result
Results for "
BV2
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-W050044
-
-
-
- HY-W019670
-
-
-
- HY-111815A
-
|
ac4CTP sodium
|
Endogenous Metabolite
|
Others
|
|
N4-Acetylcytidine triphosphate sodium is efficiently used as a substrate in T7 Polymerase-catalyzed in vitro
transcription and it can be incorporated into multiple templates .
|
-
-
- HY-B1715
-
|
ISF2522
|
GABA Receptor
NO Synthase
|
Neurological Disease
Inflammation/Immunology
|
|
Oxiracetam (ISF2522) is an orally active and a BBB-penetrable cyclic derivative of γ-aminobutyric acid (GABA). Oxiracetam reaches the hippocampus and cerebral cortex in high concentrations. Oxiracetam can promote cognitive function and regulate inflammatory response, with powerful neuroprotective effects. Oxiracetam can be used in the study of central nervous system diseases [2] .
|
-
-
- HY-B1114
-
|
AR-DF 26
|
Potassium Channel
ERK
STAT
NF-κB
COX
Interleukin Related
Reactive Oxygen Species (ROS)
|
Metabolic Disease
|
|
Gliquidone can bind to the pancreatic β-cells and increases insulin release to regulate blood glucose levels. Gliquidone significantly decreases LPS (HY-D1056)-induced proinflammatory responses and inhibits ERK/STAT3/NF-κB phosphorylation in BV2 microglial cells. Gliquidone can suppress microgliosis, microglial hypertrophy mediated by LPS, and proinflammatory cytokine COX-2 and IL-6 levels in murine model. Gliquidone also exhibits good anticancer activity in lung carcinoma cells. Gliquidone has antioxidant property. Gliquidone can be studied in research for type 2 diabetes and cancers [2].
|
-
-
- HY-N2259
-
|
(+)-Curcumenol
|
Cytochrome P450
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Curcumenol ((+)-Curcumenol) is a potent CYP3A4 inhibitor with an IC50 of 12.6 μM, which is one of constituents in the plants of medicinally important genus of Curcuma zedoaria, with neuroprotection, anti-inflammatory, anti-tumor and hepatoprotective activities. Curcumenol ((+)-Curcumenol) suppresses Akt-mediated NF-κB activation and p38 MAPK signaling pathway in LPS-stimulated BV-2 microglial cells [2].
|
-
-
- HY-101364
-
CHPG
4 Publications Verification
|
mGluR
NF-κB
ERK
Akt
|
Cardiovascular Disease
Inflammation/Immunology
|
|
CHPG is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells . CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways [2].
|
-
-
- HY-174378
-
|
|
TREM receptor
|
Neurological Disease
|
|
TREM2 agonist-4 (Compound 4a) is a TREM2 agonist with a Kd value of 45.9 μM. TREM2 agonist-4 can activate downstream signaling pathways of TREM2 and enhance the phagocytic function of microglia. TREM2 agonist-4 can be used in the research of neurodegenerative diseases such as Alzheimer's disease .
|
-
-
- HY-151108
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Neurological Disease
Inflammation/Immunology
|
|
IDO1/TDO-IN-4 is a potent IDO1/TDO dual inhibitor, with IC50 values of 3.53 μM (IDO1) and 1.15 μM (TDO). IDO1/TDO-IN-4 forms hydrogen bond with IDO1, and π−π stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression, and depression-induced infectious, metabolic, and autoimmune disorders .
|
-
-
- HY-101364A
-
|
|
mGluR
NF-κB
ERK
Akt
|
Neurological Disease
Inflammation/Immunology
|
|
CHPG sodium salt is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells . CHPG sodium salt protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways. [2].
|
-
-
- HY-N0506
-
|
|
Interleukin Related
|
Neurological Disease
|
|
Rosarin is a cinnamyl alcohol?glycoside isolated from?Rhodiola rosea. Rosarin has anti-inflammatory and neuroprotective effects. Rosarin supresses the expression of the proinflammatory factors iNOS, IL-1?β, and TNF- α in the kidney and prefrontal cortex of brain in mice? .
|
-
-
- HY-N0911
-
-
-
- HY-B0780
-
-
-
- HY-N5025
-
|
|
P2X Receptor
Apoptosis
ERK
p38 MAPK
c-Myc
NF-κB
Reactive Oxygen Species (ROS)
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Bullatine A, a diterpenoid alkaloid, is a potent P2X7 antagonist. Bullatine A possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A inhibits ATP-induced BV-2 cell death/apoptosis and P2X receptor-mediated inflammatory responses. Bullatine A suppresses glioma cell growth by targeting SIRT6. Bullatine A specifically attenuates pain hypersensitivity in rats. Bullatine A attenuates LPS (HY-D1056)-induced systemic inflammatory response by inhibiting the ROS/JNK/NF-κB pathway in mice. Bullatine A improves despair behavior in Chronic chronic social defeat stress (CSDS) mice. Bullatine A can be used for the study of inflammation, glioblastoma (GBM) and depression [2] .
|
-
-
- HY-N8371
-
|
|
NO Synthase
COX
Interleukin Related
TNF Receptor
|
Inflammation/Immunology
|
|
Shizukaol B is a lindenane-type dimeric sesquiterpene, used to be isolated from the whole plant of Chloranthus henryi. Shizukaol B has anti-inflammatory effect against lipopolysaccharide (LPS)-induced activation of BV2 microglial cells. Shizukaol B inhibits iNOS and COX-2, and suppresses NO production, TNF-α, and IL-1β expression .
|
-
-
- HY-152026
-
|
|
NADPH Oxidase
|
Neurological Disease
|
|
NADPH oxidase-IN-1 is an orally active NADPH oxidase (Nox) inhibitor, related with neuronal inflammation. NADPH oxidase-IN-1 can cross the blood-brain barrier (BBB), inhibits Nox2 and Nox4 with IC50s of 1.9 μM and 2.47 μM, respectively. NADPH oxidase-IN-1 suppresses pro-inflammatory cytokines production and LPS-mediated microglial migration, also has in vivo efficacy .
|
-
-
- HY-126066
-
-
-
- HY-171705
-
|
|
Keap1-Nrf2
AMPK
JNK
IKK
p38 MAPK
NO Synthase
α-synuclein
Interleukin Related
|
Neurological Disease
|
|
KMS99220 is an orally active, blood-brain barrier-permeable activator of the Nrf2 inhibitory protein Keap-1. KMS99220 enhances the activity of AMPK, activates the Nrf2 signaling pathway, and reduces the phosphorylation of IκB, nuclear translocation of NFκB, as well as the phosphorylation levels of JNK, IKK and p38 MAPK via HO-1. KMS99220 binds to Keap1 to trigger the nuclear translocation of Nrf2, induces the expression of HO-1, NQO1, GCLC, GCLM and proteasome subunits; enhances proteasomal enzymatic activity; inhibits iNOS expression, nitric oxide production and IL-1β generation; attenuates microglial activation; reduces α-synuclein aggregation; and prevents dopaminergic neuron degeneration and motor dysfunction. KMS99220 prevents the degeneration of dopaminergic neurons in the substantia nigra, induces the expression of Nrf2 downstream target genes, and effectively ameliorates associated motor dysfunction in a mouse model of Parkinson's disease. KMS99220 is applicable to research related to Parkinson's disease [2] .
|
-
-
- HY-149202
-
|
|
PGE synthase
|
Neurological Disease
Inflammation/Immunology
|
|
UT-11 is a potent and blood-brain barrier-permeable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor with IC50s of 0.10 μM and 2.00 μM for inhibiting PGE2 production in human (SK-N-AS) and murine (BV2) cells, respectively .
|
-
-
- HY-N3979
-
-
-
- HY-146195
-
-
-
- HY-146005
-
|
|
Microtubule/Tubulin
|
Neurological Disease
Inflammation/Immunology
|
|
Tau-aggregation and neuroinflammation-IN-1 is a potent tau-aggregation and neuroinflammation inhibitor. Tau-aggregation and neuroinflammation-IN-1 exhibits remarkable inhibitory activities against AcPHF6 and full-length tau aggregation. Tau-aggregation and neuroinflammation-IN-1 has a low cytotoxicity and reduced NO release in LPS-stimulated BV2 cells. Tau-aggregation and neuroinflammation-IN-1 can reverse okadaic acid-induced memory impairment in rats .
|
-
-
- HY-164049
-
|
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
TG8-260 is a second-generation EP2 antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. TG8-260 can reduce neuroinflammation and gliosis in the hippocampus of rats after pilocarpine-induced persistent epileptic status. Pharmacokinetic data of TG8-260 showed that its plasma half-life was 2.14 hours and its oral bioavailability was 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia, which is suitable for studying anti-inflammatory pathways in animal models of peripheral inflammatory diseases .
|
-
-
- HY-155850
-
|
|
Pyruvate Kinase
|
Neurological Disease
|
|
CIAC001 is a Pyruvate Kinase PKM2 inhibitor with anti-neuroinflammatory activity. CIAC001 inhibits LPS-induced proinflammatory nitric oxide (NO) production and protects immunologically active BV-2 cells (IC50=2.5 μM). CIAC001 also has anti-neuroinflammation in mouse models and inhibits chronic morphine-induced addiction .
|
-
-
- HY-W019670R
-
-
-
- HY-172450
-
-
-
- HY-144765
-
|
|
NF-κB
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
NF-κB-IN-4 (compound 17) is a potent NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .
|
-
-
- HY-N8631
-
|
Acetylschisantherin L
|
NO Synthase
|
Inflammation/Immunology
|
|
O-Acetylschisantherin L (Acetylschisantherin L) is a natural lignan, which exhibits inhibitory effects on LPS-induced NO production in BV-2 cells with an IC50 of 23.1 μM .
|
-
-
- HY-P11741
-
|
|
Exosomes
Biochemical Assay Reagents
|
Neurological Disease
|
|
BV2 is a delivery peptide that binds to BVES, with a Ka of 2.03 μM for the BVES target. BV2 specifically binds to the extracellular domain of BVES, achieving muscle homing and cellular internalization via caveolae-mediated endocytosis. When BV2 is modified on the surface of exosomes by PMO, it enhances dystrophin restoration in the peripheral muscles and myocardium of dystrophin-deficient mice. BV2 is applicable to research related to Duchenne muscular dystrophy and muscle atrophy .
|
-
-
- HY-N10782
-
-
-
- HY-176402
-
-
-
- HY-N11657
-
|
Sanggenone A
|
NF-κB
Keap1-Nrf2
|
Inflammation/Immunology
|
|
Sanggenon A (Sanggenone A) exerts anti-inflammatory effects by regulating NF-κB and HO-1/Nrf2 signaling pathways in BV2 and RAW264.7 cells. Sanggenon A markedly inhibits the Lipopolysaccharide (LPS; HY-D1056)-induced production of nitric oxide .
|
-
-
- HY-138050
-
|
(-)-Nyasol; (Z)-Hinokiresinol; cis-Hinokiresinol
|
NO Synthase
Bacterial
Fungal
Parasite
Leukotriene Receptor
|
Infection
Inflammation/Immunology
|
|
Nyasol ((-)-Nyasol) is an active compound that has antifungal, antibacterial, antileishmanial, hyaluronidase inhibition activities. Nyasol inhibits LTB4 binding to human neutrophils. Nyasol suppresses neuroinflammatory response through the inhibition of I-κB degradation in LPS (HY-D1056)-stimulated BV-2 microglial cells [2].
|
-
-
- HY-N2259R
-
|
(+)-Curcumenol (Standard)
|
Reference Standards
Cytochrome P450
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Curcumenol ((+)-Curcumenol) is a potent CYP3A4 inhibitor with an IC50 of 12.6 μM, which is one of constituents in the plants of medicinally important genus of Curcuma zedoaria, with neuroprotection, anti-inflammatory, anti-tumor and hepatoprotective activities. Curcumenol ((+)-Curcumenol) suppresses Akt-mediated NF-κB activation and p38 MAPK signaling pathway in LPS-stimulated BV-2 microglial cells [2].
|
-
-
- HY-N4190
-
|
1,6-O,O-Diacetylbritannilactone; Di-O-acetylbritannilactone
|
NO Synthase
|
Neurological Disease
Inflammation/Immunology
|
|
Britannilactone diacetate (1,6-O,O-Diacetylbritannilactone; Compound 2) exhibits potential NO inhibition effect. Britannilactone diacetate exhibits activity against NO production induced by LPS in BV-2 microglial cells with the EC50 value of 6.3 μM. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) penetration and absorption, distribution, metabolism, excretion, and toxicity (ADMET) property .
|
-
-
- HY-111815
-
|
ac4CTP
|
Endogenous Metabolite
|
Metabolic Disease
|
|
N4-Acetylcytidine triphosphate is efficiently used as a substrate in T7 Polymerase-catalyzed in vitro transcription and can be incorporated into multiple templates .
|
-
-
- HY-176266
-
|
|
Mitochondrial Metabolism
|
Neurological Disease
|
|
KIT-13 is an orally active plasmalogen derivative to inhibit neuroinflammation and mitochondrial DNA leakage associated with Mecp2 deficiency. KIT-13 significantly reduce neurological symptoms and improves the life span of the Rett Syndrome (RTT) model mice. KIT-13 can be used for the study of RTT and other neuroinflammation-related diseases.
|
-
-
- HY-N8090
-
|
|
NO Synthase
|
Inflammation/Immunology
|
|
(3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid, a lanostane triterpenoids, exhibits obvious NO inhibitory activity on n LPS-induced BV-2 microglia cells with an IC50 of 9.55 uM. (3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid has anti-inflammatory activities .
|
-
-
- HY-N10386
-
-
-
- HY-N2968
-
|
(+)-Bullatantriol
|
Others
|
Inflammation/Immunology
|
|
Bullatantriol ((+)?-?Bullatantriol) can be isolated from the roots of Homalomena aromatica. Bullatantriol can promote the proliferation and differentiation of osteoblasts. Bullatantriol also inhibits LPS-induced NO production in BV2 cells .
|
-
-
- HY-N15566
-
|
|
Drug Derivative
|
Neurological Disease
Inflammation/Immunology
|
|
Theleganbanin D is a p-terphenyl derivative found in the Thelephora ganbajun. Theleganbanin D inhibits TNF-α, IL-6, and IL-1β production in LPS-induced BV-2 microglial cells. Theleganbanin D is promising for research of neurodegenerative diseases .
|
-
-
- HY-178356
-
|
|
Cholinesterase (ChE)
nAChR
Interleukin Related
TNF Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
BChE-IN-44 is a potent, brain-penetrant, highly selective BChE inhibitor [equine BChE IC50 = 18.00 pM, human BChE IC50 = 1.50 nM]. BChE-IN-44 shows neuroprotective effects against the Aβ1-42-induced injury model and inhibitory effects on Aβ1-42 self-aggregation. BChE-IN-44 reduces the levels of inflammatory factors (NO, IL-6, and TNF-α) in Lipopolysaccharides (HY-D1056)-induced BV2 cells. BChE-IN-44 can significantly ameliorate Scopolamine (HY-N0296)-induced cognition impairment. BChE-IN-44 exhibits capacity in the regulation of BChE and acetylcholine levels in the mouse hippocampus. BChE-IN-44 can be used for the study of Alzheimer’s disease (AD) .
|
-
-
- HY-N10066
-
-
-
- HY-N3760
-
-
-
- HY-N11945
-
|
Kadsulignan J
|
NO Synthase
|
Others
|
|
Schiarisanrin A (Kadsulignan J) is a lignan with inhibitory activity on NO production. Schiarisanrin A inhibits NO production in BV-2 cells with an IC50 of 9.6 μM .
|
-
-
- HY-N10119
-
|
|
p38 MAPK
|
Neurological Disease
|
|
Ganoderterpene A attenuates LPS-induced inflammation and apoptosis via suppressing MAPK and TLR-4/NF-κB pathways in BV-2 cells.
|
-
-
- HY-N11943
-
|
|
NO Synthase
|
Others
|
|
Kadsulignan H (compound 13) is a lignan with inhibitory activity on NO production. Kadsulignan H inhibits NO production in BV-2 cells with an IC50 of 14.1 μM .
|
-
-
- HY-W095499
-
-
-
- HY-N12525
-
|
|
Others
|
Inflammation/Immunology
|
|
Bartsioside is an anti-inflammatory agent which can be extracted from C. deserticola. Bartsioside exerts no significant cytotoxicity under 40 μM to BV-2 cells .
|
-
-
- HY-N10275
-
|
|
Others
|
Inflammation/Immunology
|
|
Herpotrichone A shows potent anti-neuroinflammatory activity in lipopolysaccharide (LPS)-induced BV-2 microglial cells with the half maximal inhibitory concentration (IC50) value of 0.41 μM.
|
-
- HY-N0859B
-
|
|
NO Synthase
|
Neurological Disease
|
|
Schisanchinin D is an NO release inhibitor found in the fruits of Schisandra chinensis. Schisanchinin D can inhibit the release of nitric oxide (NO) by lipopolysaccharide (LPS)-activated microglia in primary murine BV2 microglia cells. Schisanchinin D is promising for research of neurodegenerative diseases such as Alzheimer's disease (AD) [2].
|
-
- HY-N12527
-
|
|
NF-κB
|
Others
|
|
Hyperelamine A (compound 5) is a polycyclic polyprenylated acylphloroglucinols (PPAPs). Hyperelamine A exhibits inhibitory activity against LPS-activated NO production in BV-2 cells via TLR-4/NF κB signaling .
|
-
- HY-119465
-
|
|
Fungal
|
Others
|
|
Restricticin is a compound obtained from marine fungi, whose structure contains alkene, tetrahydropyran ring and glycine ester functional groups, and has anti-neuroinflammatory effects in lipopolysaccharide-induced BV-2 microglia by inhibiting the production of proinflammatory mediators.
|
-
- HY-168091
-
|
|
NOD-like Receptor (NLR)
Interleukin Related
|
Inflammation/Immunology
|
|
YM-I-26 is a selective NLRP3 inflammasome inhibitor. YM-I-26 enhances the phagocytosis of β-amyloid protein by mouse microglial BV2 cells and inhibits the production of IL-1β and IL-10. YM-I-26 can be used to study the immunomodulatory activity associated with inflammation .
|
-
- HY-N3473
-
|
|
NO Synthase
|
Neurological Disease
|
|
Isomaculosidine is an alkaloid that can be isolated from D. dasycarpus. Isomaculosidine can inhibit nitric oxide (NO) production in lipopolysaccharide (LPS)-stimulated BV2 microglial cells .
|
-
- HY-N9675
-
|
|
NO Synthase
|
Inflammation/Immunology
|
|
(+)-Hannokinol can be isolated from AMOMUM TSAO-KO (ginger family) fruit. (+)-Hannokinol inhibits lipopolysaccharide-induced nitric oxide production in BV2 microglia .
|
-
- HY-155762
-
-
- HY-P10350
-
|
|
NF-κB
|
Neurological Disease
Inflammation/Immunology
|
|
PapRIV is an agonist of BV-2 microglial cells, capable of activating microglial cells through an NF-κB-dependent pathway. PapRIV induces the expression of pro-inflammatory cytokines such as IL-6 and TNFα and increases the production of reactive oxygen species (ROS). PapRIV can cross the blood-brain barrier .
|
-
- HY-153690
-
|
|
TNF Receptor
|
Others
|
|
Progranulin modulator-1 (Compound 60) is an orally active enhancer of progranulin (PGRN) secretion. Progranulin modulator-1 enhances the potency of BV-2 cell to increase PGRN levels, has inhibitory effect on hERG and Low cytotoxicity, the PGRN EC50 and hERG IC50 were 83 and 3100 nM, respectively .
|
-
- HY-146168
-
|
|
Keap1-Nrf2
|
Inflammation/Immunology
|
|
Nrf2 activator-5 (compound 1) is a potent Nrf2 activator that can attenuate H2O2-induced oxidative stress and LPS-stimulated inflammation in BV-2 microglial cells. Nrf2 activator-5 exhibits antioxidant and anti-inflammatory activities .
|
-
- HY-N7018
-
|
|
Others
|
Inflammation/Immunology
|
|
20-Hydroxyganoderic Acid G is a lanostane triterpenoid obtained from the EtOH extract of fruiting bodies of the Ganoderma curtisii. 20-Hydroxyganoderic Acid G inhibits BV-2 microglia cells activated by LPS with an IC50 of 21.33 μM. 20-Hydroxyganoderic Acid G has therapeutic potential in the agent discovery of nerve inflammation diseases associated with microglia activated by LPS .
|
-
- HY-155572
-
|
|
Keap1-Nrf2
|
Inflammation/Immunology
|
|
Nrf2 activator-8 (compound 10e) is a Nrf2 activator (EC50=37.9 nM). Nrf2 activator-8 exhibits remarkable antioxidant and anti-inflammatory effects in BV-2 microglial cells. Nrf2 activator-8 can significantly restore spatial memory deficits in a mouse model of lipopolysaccharide (LPS)-induced neuroinflammation .
|
-
- HY-N15570
-
|
|
Interleukin Related
TNF Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
2-O-Methylatromentin is an anti-neuroinflammatory agent. 2-O-Methylatromentin shows inhibitory activity on the production of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β in Lipopolysaccharides (HY-D1056) (LPS) -induced BV-2 microglial cells. 2-O-Methylatromentin can be used for the study of neuroinflammatory related diseases .
|
-
- HY-N8936
-
|
|
Others
|
Inflammation/Immunology
|
|
Narchinol B (Compound 4) is a sesquiter penoid
compound. Narchinol B has anti-inflammatory effects. Narchinol B works by
inhibiting proinflammatory mediators, including prostaglandin E2 (PGE2),
inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) proteins,
as well as proinflammatory cytokines, such as interleukin-1b, IL-6, and tumor
necrosis factor-α (TNF-α). Narchinol B significantly inhibits LPS-induced
overproduction of NO in BV2 cells (IC50=2.43 μM)
.
|
-
- HY-161925
-
|
|
TGF-β Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
sTGFBR3 antagonist 1 (Compound p24) is an antagonist for soluble transforming growth factor beta receptor 3 (sTGFBR3), thus activates TGF-β signaling pathway, and inhibits IκBα/NF-κB signaling pathway. sTGFBR3 antagonist 1 inhibits NO-release in LPS (HY-D1056) -induced BV2 cells with an IC50 of 0.52 μM. sTGFBR3 antagonist 1 exhibits anti-inflammatory and neuroprotective activities with blood brain barrier (BBB) permeability. sTGFBR3 antagonist 1 can be used in Alzheimer’s Disease research .
|
-
- HY-N13701
-
|
|
NO Synthase
|
Inflammation/Immunology
|
|
3β,7β,15α-Trihydroxy-4-(hydroxymethyl)-11,23-dioxo-lanost-8-en-26-oic acid is a triterpene compound that can be found in Ganoderma lucidum, and it inhibits nitric oxide (NO) production in BV-2 microglial cells induced by lipopolysaccharide (LPS, HY-D1056), with an IC50 of 4.15 μM .
|
-
- HY-N0894A
-
|
(3R,5R)-Hexahydrobisdemethoxycurcumin
|
Drug Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
(3R,5R)-Octahydrocurcumin (Compound 7) is gut microbial metabolite of Curcumin (HY-N0005). (3R,5R)-Octahydrocurcumin exhibits neuroprotective efficacy against Aβ25-35-induced cell damage in SH-SY5Y, and anti-inflammatory activity against LPS-stimulated mouse microglial BV-2 .
|
-
- HY-N13706
-
|
|
NO Synthase
|
Inflammation/Immunology
|
|
3β,15α-Dihydroxy-7,11,23-trioxo-lanost-8-dien-26-oic acid is a triterpene compound that can be found in Ganoderma lucidum, and it inhibits nitric oxide (NO) production in BV-2 microglial cells induced by lipopolysaccharide (LPS, HY-D1056), with an IC50 of 6.50 μM, making it a potential candidate for anti-inflammatory research .
|
-
- HY-N16626
-
|
|
Others
|
Inflammation/Immunology
|
|
Chantriolide B is a new withanolide glucoside. Chantriolide B can be isolated from the rhizomes of Tacca chantrieri. Chantriolide B does not inhibit NO in cells [2].
|
-
- HY-172451
-
-
- HY-172540
-
-
- HY-N3814
-
|
|
Others
|
Inflammation/Immunology
|
|
ent-16β,17-Dihydroxykauran-19-oic acid is an anti-inflammatory agent, which can be isolated from Siegesbeckia pubescens herb. ent-16β,17-Dihydroxykauran-19-oic acid inhibits lipopolysaccharide-induced nitric oxide production in BV2 microglia .
|
-
- HY-N0506R
-
|
|
Reference Standards
Interleukin Related
|
Neurological Disease
|
|
Rosarin (Standard) is the analytical standard of Rosarin. This product is intended for research and analytical applications. Rosarin is a cinnamyl alcohol glycoside isolated from Rhodiola rosea. Rosarin has anti-inflammatory and neuroprotective effects. Rosarin supresses the expression of the proinflammatory factors iNOS, IL-1 β, and TNF- α in the kidney and prefrontal cortex of brain in mice .
|
-
- HY-101364AR
-
|
|
Reference Standards
mGluR
NF-κB
ERK
Akt
|
Neurological Disease
Inflammation/Immunology
|
|
CHPG (sodium salt) (Standard) is the analytical standard of CHPG (sodium salt). This product is intended for research and analytical applications. CHPG sodium salt is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells . CHPG sodium salt protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways. [2].
|
-
- HY-W841438
-
|
|
Amyloid-β
Tau Protein
|
Neurological Disease
|
|
Lithium orotate is an orally active lithium supplement with reduced binding that can bypass amyloid sequestration in AD mice models. Lithium orotate can prevent Aβ plaque deposition and phospho-tau accumulation and reverse AD pathology, neuroinflammatory changes and memory loss in AD mice models and ageing wild-type mice. Lithium orotate can be used for the research of alcoholism and Alzheimer’s disease [2].
|
-
- HY-W050044R
-
-
- HY-168563
-
|
|
Cholinesterase (ChE)
FAAH
|
Neurological Disease
|
|
BuChE-IN-15 (compound D12) is a selective BuChE/FAAH dual inhibitor with and show IC50 values of 81 and 400 nM for hBuChE and hFFAH, respectively. BuChE-IN-15 possesses good BBB penetration, and shows neuroprotection.BuChE-IN-15 can be used for study of Alzheimer .
|
-
- HY-174339
-
|
|
Phosphodiesterase (PDE)
Heme Oxygenase (HO)
NF-κB
|
Neurological Disease
Inflammation/Immunology
|
|
Neuroprotective agent 12 is an orally active and BBB-penetrable neuroprotective agent. Neuroprotective agent 12 has potent neuroprotective effects with robust anti-oxidation and anti-inflammation. Neuroprotective agent 12 significantly inhibits glutamate- and acrolein-induced cell death, reduces PDE4B expression but increases the HO-1, p-CREB and BDNF levels. Neuroprotective agent 12 exhibits potent neuroprotection in traumatic brain injury (TBI) mice model, promising for TBI and other central nervous system diseases .
|
-
- HY-178433
-
|
|
Cholinesterase (ChE)
p38 MAPK
|
Neurological Disease
|
|
BChE/p38-α MAPK-IN-2 is a BChE and p38-α MAPK dual inhibitor. BChE/p38-α MAPK-IN-2 inhibits hBChE with an IC50 of 5.1 nM, showing 1000-fold selectivity over hAChE. BChE/p38-α MAPK-IN-2 inhibits p38α MAPK with an IC50 of 8.12 μM. BChE/p38-α MAPK-IN-2 exhibits neuroprotective effect and can be used for the research of neurological disease, such as Alzheimer’s disease .
|
-
- HY-169103
-
|
|
NO Synthase
COX
Cholinesterase (ChE)
Amyloid-β
|
Neurological Disease
Inflammation/Immunology
|
|
Neuroprotective agent 5 (compound 28) is a brain permeabilizing agent with anti-neuritis, anti-oxidative damage and neuroprotective effects. Neuroprotective agent 5 exhibits a potent NO inhibitory effect (EC50=0.49 μM), inhibits the release of proinflammatory factors PGE2 and TNF-α, downregulates the expression of iNOS and COX-2 proteins, and promotes the polarization of BV-2 cells from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype. In addition, Neuroprotective agent 5 can also inhibit acetylcholinesterase (AChE) activity and Aβ42 aggregation in a dose-dependent manner. Neuroprotective agent 5 can be used for the study of Alzheimer's disease .
|
-
- HY-B1114R
-
|
AR-DF 26 (Standard)
|
Potassium Channel
Reference Standards
ERK
STAT
NF-κB
COX
Interleukin Related
|
Metabolic Disease
|
|
Gliquidone (Standard) is the analytical standard of Gliquidone. This product is intended for research and analytical applications. Gliquidone can bind to the pancreatic β-cells and increases insulin release to regulate blood glucose levels. Gliquidone significantly decreases LPS (HY-D1056)-induced proinflammatory responses and inhibits ERK/STAT3/NF-κB phosphorylation in BV2 microglial cells. Gliquidone can suppress microgliosis, microglial hypertrophy mediated by LPS, and proinflammatory cytokine COX-2 and IL-6 levels in murine model. Gliquidone also exhibits good anticancer activity in lung carcinoma cells. Gliquidone has antioxidant property. Gliquidone can be studied in research for type 2 diabetes and cancers [2].
|
-
- HY-N15564
-
|
|
Drug Derivative
|
Neurological Disease
Inflammation/Immunology
|
|
Theleganbanin B is a p-terphenyl derivative found in the Thelephora ganbajun. Theleganbanin B inhibits TNF-α, IL-6, and IL-1β production in LPS-induced BV-2 microglial cells. Theleganbanin B inhibits the phosphorylation of JAK2/STAT3. Theleganbanin B is promising for research of neurodegenerative diseases .
|
-
- HY-N10274
-
-
- HY-N13831
-
|
|
Others
|
Others
|
|
Swietenidine B is a quinoline alkaloid that can be isolated from the root bark of Dictamnus dasycarpus. Swietenidine B does not show significant activity in inhibiting NO production in LPS-induced BV-2 microglial cells .
|
-
- HY-167853
-
|
SK-1080
|
Angiotensin Receptor
|
Metabolic Disease
|
|
KR-31080 is an derivative of imidazo [4,5-b] pyridine. KR-31080 inhibits angiotensin II receptor. KR-31080 inhibits the NO production in LPS-stimulated BV-2 cells at a concentration of 2 μm with inhibition of 8.3% .
|
-
- HY-N10458
-
|
|
NF-κB
|
Inflammation/Immunology
|
|
Asperbisabolane L, a sesquiterpenoid, exerts the anti-inflammatory activity by inhibiting the NF-κB-activated pathway. Asperbisabolane L inhibits the translocation of NF-κB from cytoplasm to the nucleus. Asperbisabolane L also inhibits NO production in LPS-activated BV-2 microglia cells .
|
-
- HY-N19854
-
|
|
NO Synthase
|
Neurological Disease
|
|
Mariaterpenoside A is an inducible nitric oxide synthase (iNOS) inhibitor. Mariaterpenoside A interacts with the active cavity of iNOS protein via hydrogen bonds with specific residues of the binding site. Mariaterpenoside A suppresses NO release in LPS (HY-D1056)-induced murine microglial BV-2 cells. Mariaterpenoside A can be used for the research of neurodegenerative disease .
|
-
- HY-N13729
-
|
|
NO Synthase
|
Cardiovascular Disease
Neurological Disease
|
|
Stephalonine P is a hasubanan-type alkaloid anti-inflammatory agent with neuroprotective effects against neuroinflammation. Stephalonine P regulates post-ischemic inflammatory responses by inhibiting NO production in LPS-activated BV2 microglia (IC50=34.01 μM), thereby reducing microglial activation and neuronal damage. Stephalonine P can be isolated from the whole plant of Stephania japonica. Stephalonine P can be used in research on stroke and other neuroinflammation-related diseases .
|
-
- HY-N15565
-
-
- HY-N1263
-
|
|
NO Synthase
|
Inflammation/Immunology
|
|
Scutebarbatine X (Compound 2) is a neo-clerodane diterpenoids isolated from Scutellaria barbatae (Labiatae) and has anti-inflammatory properties .
|
-
- HY-180889
-
|
|
PROTACs
Epigenetic Reader Domain
|
Neurological Disease
Inflammation/Immunology
|
|
PROTAC BRD3 degrader-1 (compound D072) is a potent and selective PROTAC BRD3 degrader. PROTAC BRD3 degrader-1 selectively degrades BRD3 in mice, leading to the downregulation of H3K18ac without affecting BRD2 or BRD4. PROTAC BRD3 degrader-1 reduces intraocular inflammation in the experimental autoimmune uveitis (EAU) mouse mode and inhibits proinflammatory microglia in both uveitis retina and LPS (HY-D1056) treated mouse microglia cell line BV2. PROTAC BRD3 degrader-1 can be used for uveitis research .
|
-
- HY-116426
-
|
|
Tau Protein
TNF Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
IDT is a safe and effective TNFα and innate immune system modulator. IDT significantly reduced paired helical filament tau and fibrillar amyloid accumulation and increased the infiltrating neutrophil population while reducing TNFα expression in this population. IDT can be used in Alzheimer's disease research .
|
-
- HY-143413
-
|
|
Amyloid-β
|
Neurological Disease
Inflammation/Immunology
|
|
BuChE-IN-2 is an excellent butyrylcholinesterase (BuChE) inhibitor (IC50s of 1.28 μM and 0.67 μM for BuChE and NO). BuChE-IN-2 can inhibit the aggregation of Aβ, ROS formation and chelate Cu 2+, exhibiting proper blood-brain barrier (BBB) penetration. BuChE-IN-2 has potential to research Alzheimer’s disease .
|
-
- HY-131616
-
|
|
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
|
|
Ethyl α-eleostearate is isolated from the ethanolic extract of Pseudo-nitzschia australis (PAEE). The PAEE of Pseudomonas australis has anti-neuroinflammatory effects, inhibiting intracellular ROS as well as pro-inflammatory mediators and cytokines .
|
-
- HY-173513
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Neurological Disease
|
|
IDO1/TDO-IN-8 (Compound CZ-17) is a dual IDO1 and TDO inhibitor that can penetrate the blood-brain barrier, with EC50 values of 0.33 μM and 1.78 μM, respectively. IDO1/TDO-IN-8 reduces the kynurenine/tryptophan ratio by regulating the kynurenine pathway of tryptophan metabolism. IDO1/TDO-IN-8 has a neuroprotective effect and can alleviate motor dysfunction and improve depressive behavior. IDO1/TDO-IN-8 can be used in the study of Parkinson's disease combined with depression .
|
-
- HY-151386
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
BChE-IN-13 (Compound 17c) is an orally active, potent and selective Butyrylcholinesterase (BChE) inhibitor with IC50s of 0.22 and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 can improve memory and cognitive impairments, and be used in Alzheimer’s disease (AD) research .
|
-
- HY-181124
-
|
Idebenone-2S-FrFK-NH2
|
Drug Derivative
Reactive Oxygen Species (ROS)
Mitochondrial Metabolism
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Idebenone-SS-20 (Idebenone-2S-FrFK-NH2) is a Idebenone (HY-N0303) derivative conjugated to the mitochondria-targeting peptide SS-20. Idebenone-SS-20 shows neuroprotective and anti-inflammatory effects. Idebenone-SS-20 can preserve mitochondrial membrane potential, enhance ATP production, reduce ROS accumulation, maintain mitochondrial morphology and elevate NAD+/NADH ratio. Idebenone-SS-20 confers robust neuroprotection in a murine model of transient middle cerebral artery occlusion. Idebenone-SS-20 can be used for the research of cerebral .
|
-
- HY-N18031
-
|
|
NO Synthase
|
Inflammation/Immunology
|
|
Idesin is a compound found in the fruits of Idesia polycarpa. Idesin inhibits LPS (HY-D1056)-induced nitric oxide production with mild cytotoxicity .
|
-
- HY-N18012
-
|
|
NO Synthase
|
Inflammation/Immunology
|
|
Pratialin B is a C14-polyacetylenol glycoside analog found in the roots of Codonopsis pilosula. Pratialin B exhibits weak inhibitory activity against LPS (HY-D1056)-induced NO production .
|
-
- HY-181069
-
-
- HY-N9164
-
-
- HY-183760
-
|
|
Cholinesterase (ChE)
HSP
GSK-3
Amyloid-β
|
Neurological Disease
Inflammation/Immunology
|
|
AChE/BChE-IN-37 is a blood-brain barrier-permeable AChE/BChE inhibitor, with an IC50 of 73.65 μM against electric eel-derived AChE and an IC50 of 82.93 μM against horse-derived BChE. AChE/BChE-IN-37 exhibits chelating activity towards Cu 2+, Ca 2+, Mg 2+, Fe 2+ and Zn 2+. AChE/BChE-IN-37 interacts with HSP90AA1 and GSK-3β. AChE/BChE-IN-37 inhibits the self-induced aggregation of Aβ1-42. AChE/BChE-IN-37 suppresses LPS-induced NO production in cells. AChE/BChE-IN-37 can be used in research related to Alzheimer's disease and inflammatory diseases .
|
-
- HY-N0761A
-
|
trans-3-Hydroxy-4-methoxycinnamic acid
|
NO Synthase
Prostaglandin Receptor
PI3K
Akt
NF-κB
Keap1-Nrf2
COX
|
Metabolic Disease
Inflammation/Immunology
|
|
trans-Isoferulic acid (trans-3-Hydroxy-4-methoxycinnamic acid) is an aromatic acid that exhibits anti-inflammatory activity. trans-Isoferulic acid dephosphorylates PI3K/Akt, suppresses LPS (HY-D1056)-induced NF-κB activation, enhances Nrf2 activity, downregulates iNOS and COX-2 expression, induces HO-1 expression, inhibits NO and PGE2 production, and scavenges hydroperoxyl radical. trans-Isoferulic acid can be used for research of inflammatiory diseases [2] .
|
-
- HY-182777
-
|
|
HDAC
NO Synthase
TNF Receptor
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
HDAC6-IN-80 is an orally active, selective HDAC6 inhibitor with an IC50 of 8.5 nM. HDAC6-IN-80 inhibits lipopolysaccharide-induced microglial activation, reduces the levels of iNOS, COX-2, TNF-α and IL-6, and alleviates sensory hypersensitivity behaviors. HDAC6-IN-80 can be used for the research of inflammatory pain and chemotherapy-induced peripheral neuropathy .
|
-
- HY-173414
-
|
|
PROTACs
STING
NF-κB
|
Inflammation/Immunology
|
|
PROTAC STING degrader-3 is a STING PROTAC degrader (DC50: 0.62 μM). PROTAC STING degrader-3 induces STING degradation via the ubiquitin-proteasome pathway. PROTAC STING degrader-3 exerts anti-inflammatory effects by inhibiting STING/TBK1/NF-κB signaling. PROTAC STING degrader-3 has renal protective effects and can be used in the study of acute kidney injury (AKI) .
|
-
- HY-181612
-
|
|
COX
Calcium Channel
Interleukin Related
TNF Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
COX-2/CaV2.2-IN-1 is an orally active and selective dual COX-2/CaV2.2 inhibitor, exhibiting a COX-2 IC50 of 0.26 μM and a CaV2.2 IC50 of 0.29 μM. COX-2/CaV2.2-IN-1 suppresses inflammatory responses and inflammatory mediator (IL-6, TNF-α, NO) production. COX-2/CaV2.2-IN-1 produces pronounced analgesic effects in diverse models of inflammatory, neuropathic, and visceral pain. COX-2/CaV2.2-IN-1 can be used for the research of chronic pain .
|
-
- HY-12970B
-
|
|
Histone Methyltransferase
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Cancer
|
|
EPZ020411 dihydrochloride is a selective, blood-brain barrier-permeable PRMT6 inhibitor with an IC50 of 0.010 μM. EPZ020411 dihydrochloride blocks PRMT6-mediated histone H3R2 methylation, reduces ROS production, and inhibits Apoptosis. EPZ020411 dihydrochloride is applicable to research related to neuropathic pain, colorectal cancer, ototoxicity, hearing loss and glioblastoma [2] .
|
-
- HY-129440
-
|
|
NF-κB
Toll-like Receptor (TLR)
p38 MAPK
NO Synthase
COX
ERK
Caspase
PDGFR
MyD88
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
N-(p-Coumaroyl) Serotonin is an orally active polyphenol found in safflower seeds with potent anti-inflammatory, antioxidant, and antitumor activities. N-(p-Coumaroyl) Serotonin suppresses NF‑κB, TLR4/MyD88 and MAPK signaling, activates NQO1/HO‑1 pathways, and inhibits pro‑inflammatory cytokines, iNOS and COX‑2 and ROS production. N-(p-Coumaroyl) Serotonin induces S‑phase arrest and apoptosis in glioblastoma cells, reduces atherosclerotic lesions, and alleviates renal and vascular injuries. N-(p-Coumaroyl) Serotonin acts as a vasodilator, regulates calcium dynamics. N-(p-Coumaroyl) Serotonin can be used for the research of neurodegenerative diseases, atherosclerosis, glioblastoma, and acute renal failure [2] .
|
-
- HY-19009B
-
|
|
CCR
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Propagermanium is an orally active and selective CCR2 inhibitor. Propagermanium enhances IFN-γ, IL-2, 2',5'-oligoadenylate synthetase, and unspecified cytokine production, and induces mature cytolytic NK cell subsets. Propagermanium reduces HBe antigen and HBV DNA polymerase levels, promotes HBV clearance and lowers serum ALT. Propagermanium downregulates STAT1, inhibits pro-inflammatory microglia polarization, pro-inflammatory cytokine release, and monocyte/macrophage infiltration. Propagermanium can be used for the research of chronic hepatitis B, atherosclerosis, breast cancer, non-alcoholic steatohepatitis, insulin resistance, refractory gastric cancer, multiple myeloma, type 2 diabetes [2] .
|
-
- HY-183357
-
|
|
GABA Receptor
5-HT Receptor
Reactive Oxygen Species (ROS)
TNF Receptor
Interleukin Related
COX
NF-κB
IKK
NO Synthase
|
Neurological Disease
Inflammation/Immunology
|
|
GABAAR/5-HT2AR modulator-1 is an orally active and brain-penetrant GABAAR agonist and 5-HT2AR antagonist with Kd values of 0.89 and 0.78 μM. GABAAR/5-HT2AR modulator-1 blocks 5-HT-stimulated IP1 accumulation, inducing a chloride current, reduces LPS (HY-D1056)-induced increases of ROS, NO, TNF-α, IL-6, IL-1β, iNOS, and COX-2 levels. Antidepressant agent 11 dihydrochloride inhibits NF-κB pathway activation by reducing IκBα and p65 phosphorylation and blocking p65 nuclear translocation. GABAAR/5-HT2AR modulator-1 alleviates depression-like behaviors in LPS-challenged and chronic restraint stress-challenged mice, and protects hippocampal neurons against inflammation-mediated damage .
|
-
- HY-N17383
-
|
|
Toll-like Receptor (TLR)
NF-κB
Collagen
Interleukin Related
Cadherin
NOD-like Receptor (NLR)
TGF-β Receptor
FXR
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
|
|
Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease [2] .
|
-
- HY-182702
-
|
|
TREM receptor
Syk
|
Neurological Disease
|
|
As48 is a selective TREM2 agonist with a KD value of 12.48 μM in TRIC binding assay. As48 binds near the TREM2 cleavage region, forms hydrogen bonds with Gly68, reduces conformational flexibility in regions 58-102, restricts protease accessibility to the cleavage site. As48 activates SYK phosphorylation, enhances microglial phagocytosis, and induces downstream calcium signaling in TREM2-expressing cells. As48 inhibits TREM2 ectodomain shedding without affecting ADAM10/17 protease activities. As48 can be used for the research of Alzheimer's disease .
|
-
- HY-120152A
-
|
|
SphK
Interleukin Related
TNF Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
SLP7111228 hydrochloride is a selective sphingosine kinase 1 (SphK1) inhibitor and anti-inflammatory agent. SLP7111228 hydrochloride selectively inhibits SphK1 and reduces the production of sphingosine-1-phosphate. SLP7111228 hydrochloride decreases lipopolysaccharide-induced TNFα and IL-1β levels. SLP7111228 hydrochloride alleviates obliterative pulmonary arteriopathy, increases cardiac index and decreases total pulmonary vascular resistance index. SLP7111228 hydrochloride can be used in research related to neuroinflammatory diseases and pulmonary hypertension [2].
|
-
- HY-181765
-
-
- HY-101318
-
|
β-FNA hydrochloride
|
Opioid Receptor
p38 MAPK
STAT
NF-κB
NO Synthase
Toll-like Receptor (TLR)
|
Cardiovascular Disease
Neurological Disease
|
|
β-Funaltrexamine (β-FNA) hydrochloride is a blood-brain barrier-permeable, selective and irreversible μ-opioid receptor antagonist with immunomodulatory, anti-inflammatory and neuroprotective activities. β-Funaltrexamine hydrochloride inhibits p38 MAPK and TLR4 signaling by blocking μ-opioid receptors, and reduces the transcriptional activities of NF-κB, AP-1, CREB and Stat. Furthermore, β-Funaltrexamine hydrochloride inhibits iNOS activation and pro-inflammatory microglial polarization, converting microglia to an anti-inflammatory phenotype, thereby downregulating neuroinflammation and ameliorating neuronal degeneration. β-Funaltrexamine hydrochloride is widely applicable to research related to stroke, cerebral ischemia/reperfusion injury and neurodegenerative diseases [2] .
|
-
- HY-181941
-
-
- HY-174369
-
|
|
TREM receptor
Syk
|
Neurological Disease
|
|
TREM2 agonist-3 (Compound 4i) is a TREM2 agonist with a KD value of 19.0 µM. The KD value of TREM2 agonist-3 for TREM1 is 39.8 µM. TREM2 agonist-3 induces an increase in phosphorylated SYK levels. TREM2 agonist-3 can be used in the research of neurodegenerative diseases and other diseases associated with TREM2 dysfunction .
|
-
- HY-112369
-
|
|
Src
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
LDDN-0003499 is a Src family tyrosine kinase inhibitor and anti-inflammatory agent. LDDN-0003499 reduces basal and Aβ-stimulated levels of active, phosphorylated Lyn and Src kinases, and attenuates Aβ-stimulated secretion of pro-inflammatory cytokines TNFα and IL-6 in microglial cells. LDDN-0003499 can be used for the research of Alzheimer's disease .
|
-
- HY-181743
-
-
- HY-116474
-
|
|
ERK
JNK
MMP
p38 MAPK
STAT
Fungal
Bacterial
NO Synthase
PGE synthase
NF-κB
Wnt
β-catenin
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis [2] .
|
-
- HY-183352
-
|
|
Cholinesterase (ChE)
Toll-like Receptor (TLR)
p38 MAPK
Interleukin Related
Complement System
|
Neurological Disease
|
BuChE-IN-23 is an orally active, blood-brain barrier permeable butyrylcholinesterase (eqBuChE) inhibitor with an IC50 of 15.59 μM and a Ki of 29.33 μM. BuChE-IN-23 exhibits an IC50 of 38.65 μM against hBuChE and shows selectivity for butyrylcholinesterase over acetylcholinesterase. BuChE-IN-23 inhibits LPS (HY-D1056)-induced nitric oxide production, attenuates hippocampal glial cell activation and neuroinflammation, suppresses the TLR4/p38 MAPK signaling pathway, and regulates the IL-1β/C3-mediated microglia-astrocyte inflammatory axis. BuChE-IN-23 can be used for the research of Alzheimer's disease .
|
-
- HY-N6893
-
|
|
NF-κB
NOD-like Receptor (NLR)
Apoptosis
Autophagy
|
Neurological Disease
Cancer
|
Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the NACHT domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE2) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia [2] .
|
-
- HY-N10424
-
|
|
Na+/K+ ATPase
Apoptosis
Interleukin Related
NO Synthase
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Brazilein is a compound with anti-inflammatory and neuroprotective activities, with an IC50 of 500 μM against guinea pig Na +,K +-ATPase. Brazilein reduces iNOS mRNA expression, thereby inhibiting nitric oxide production in immune cells. Brazilein suppresses inflammatory responses by reducing the mRNA expression of TNF-α and IL-6, but has no effect on IL-1β expression. Brazilein reduces the cerebral infarction volume and improves the neurological function scores of rats with cerebral ischemia-reperfusion injury. Brazilein induces apoptosis of splenic lymphocytes in mice. Brazilein inhibits humoral immune responses in mice, and causes thymus and spleen atrophy as well as body weight loss in mice. Brazilein can be used in studies related to the nervous system, cardiovascular system and inflammatory diseases [2] .
|
-
- HY-N6998A
-
|
|
Others
|
Infection
Cancer
|
|
6-epi-Paederosidic acid is a cyclopentanoid monoterpene glycoside found in the aerial parts of Paederia foetida L. 6-epi-Paederosidic acid does not exhibit cytotoxic activity against human tumor cells, hepatoprotective activity against APAP (HY-66005)-induced cellular toxicity, or inhibitory activity against LPS (HY-D1056)-induced nitric oxide production in murine microglia .
|
-
- HY-12688
-
|
|
Mitochondrial Metabolism
Reactive Oxygen Species (ROS)
Amyloid-β
|
Neurological Disease
Inflammation/Immunology
|
|
Succinyl phosphonate is a α-Ketoglutarate Dehydrogenase Complex (KGDHC) modulator with neuroprotective activity. Succinyl phosphonate protects this complex, reduces cellular succinyl-CoA concentration, downregulates protein succinylation levels, and inhibits the activity of the α-ketoglutarate dehydrogenase complex. Succinyl phosphonate corrects hypoxic or ethanol-induced behavioral impairments, modulates exploratory behavior and emotional stress responses, and improves hypoxia tolerance. Succinyl phosphonate reduces glutamate excitotoxicity, restores the activity of the α-ketoglutarate dehydrogenase complex, reverses the changes in glutamate dehydrogenase and glutamine synthetase activities induced by β-amyloid (Amyloid-β), modulates cognitive function, and prevents β-amyloid-induced neuronal damage. Succinyl phosphonate improves microglial senescence, alleviates neuroinflammation, reactive oxygen species (ROS) production, lipid peroxidation, and the expression of proinflammatory cytokines. Succinyl phosphonate can be used in the research of Alzheimer's disease, aging-related neuroinflammation, and Parkinson's disease [2] .
|
-
- HY-183593
-
|
|
Phosphatase
Akt
Interleukin Related
|
Neurological Disease
|
|
SHIP1-IN-1 is an orally active, blood-brain barrier-permeable SHIP1 ligand. SHIP1-IN-1 exhibits IC50 values of 384 μM and 177 μM against human SHIP1, and an IC50 value of 379 μM against murine SHIP1. SHIP1-IN-1 alters the binding state of SHIP1 to phosphatidylinositol membranes, and regulates phosphoinositide pools and phosphorylated AKT levels. SHIP1-IN-1 enhances the uptake of myelin/membrane fragments and amyloid proteins by microglia, alters gene expression and reduces IL-1β levels. SHIP1-IN-1 can be used in studies related to Alzheimer's disease [2].
|
-
- HY-183272
-
-
- HY-N2439
-
|
|
Environmental Pollutants
Pyroptosis
SOD
Quinone Reductase
Keap1-Nrf2
NF-κB
|
Cardiovascular Disease
|
|
Methyl isoeugenol is an orally active, blood-brain barrier-permeable isoeugenol-type eugenol analog. Methyl isoeugenol promotes the nuclear translocation of Nrf2, upregulates the expressions of HO-1, NQO1 and SOD, and reduces the expression level of MDA. Methyl isoeugenol decreases the nuclear translocation of NF-κB. Methyl isoeugenol inhibits NLRP3 inflammasome-mediated pyroptosis. Methyl isoeugenol reduces cerebral infarction volume and regulates the M1/M2 phenotypic balance of microglia. Methyl isoeugenol can be used for the research of cerebral ischemia-reperfusion injury .
|
-
- HY-182469
-
|
|
Lactate Dehydrogenase
AMPK
FOXO
Interleukin Related
Reactive Oxygen Species (ROS)
TNF Receptor
Bcl-2 Family
Caspase
Apoptosis
|
Neurological Disease
|
|
FuBIG is an iminoguanidine derivative with neuroprotective effects. FuBIGL inhibits L-LDH activation and reduces lactate production. FuBIGL exerts protective effects on inflammatory nerve cells, upregulates the expressions of AMPK, pAMPK and FOXO3, and activates the AMPK pathway in cells. FuBIG exerts anti-inflammatory effects by reducing pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and increasing the anti-inflammatory cytokine IL-10. FuBIG maintains mitochondrial membrane potential, alleviates mitochondrial dysfunction, reduces ROS production, and relieves oxidative stress. FuBIG upregulates Bcl-2, downregulates Bax and Caspase-3, and inhibits cell apoptosis (apoptosis). FuBIG improves metabolic disorders in diabetic mice, decreases the levels of LDL-C, ALT and AST, and increases HDL-C level simultaneously. FuBIG can be used in the research of diabetic neuroinflammation .
|
-
- HY-164288
-
|
TDI-006570
|
Cyclic GMP-AMP Synthase
STING
|
Neurological Disease
Inflammation/Immunology
|
|
TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases [2] .
|
-
- HY-P10998
-
|
|
TET Protein
|
Neurological Disease
|
|
Tet1 peptide is a peptide that specifically binds to neurons. Tet1 peptide binds to GT1B ganglioside and trisialoganglioside clostridial toxin receptor on the surface of neuronal cells, and can be used in peptide conjugation and drug delivery research [2].
|
-
- HY-112847B
-
|
(E/Z)-Sulfo-N-succinimidyl oleate sodium
|
Transmembrane Glycoprotein
Mitochondrial Metabolism
Drug Isomer
|
Inflammation/Immunology
|
|
(E/Z)-Sulfosuccinimidyl oleate sodium is the racemate of (E)-Sulfosuccinimidyl oleate sodium and (Z)-Sulfosuccinimidyl oleate sodium. Sulfosuccinimidyl oleate sodium (Sulfo-N-succinimidyl oleate sodium) is a long-chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate sodium is a potent and irreversible inhibitor of the mitochondrial respiratory chain. Sulfosuccinimidyl oleate sodium binds to the CD36 receptor on the surface of microglial cells. Sulfosuccinimidyl oleate sodium exhibits anti-inflammatory effects [2].
|
-
- HY-121811
-
|
Lanceolatin C
|
Glycosidase
Phosphatase
Interleukin Related
TNF Receptor
COX
Beclin1
GLUT
FAK
Akt
mTOR
p38 MAPK
Keap1-Nrf2
Apoptosis
Amyloid-β
Tau Protein
Autophagy
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Pongamol is an orally active flavonoid with an IC50 of 75 μM and a Ki of 58 μM against PTPase-1B, and an IC50 of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, TNF‑α, COX‑2 and iNOS in cells, reverses the nuclear translocation of NF‑κB, and upregulates the levels of Beclin 1 and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol alleviates oxidative stress, neuroinflammation, Aβ deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia [2] .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10998
-
|
|
TET Protein
|
Neurological Disease
|
|
Tet1 peptide is a peptide that specifically binds to neurons. Tet1 peptide binds to GT1B ganglioside and trisialoganglioside clostridial toxin receptor on the surface of neuronal cells, and can be used in peptide conjugation and drug delivery research [2].
|
-
- HY-P11741
-
|
|
Exosomes
Biochemical Assay Reagents
|
Neurological Disease
|
|
BV2 is a delivery peptide that binds to BVES, with a Ka of 2.03 μM for the BVES target. BV2 specifically binds to the extracellular domain of BVES, achieving muscle homing and cellular internalization via caveolae-mediated endocytosis. When BV2 is modified on the surface of exosomes by PMO, it enhances dystrophin restoration in the peripheral muscles and myocardium of dystrophin-deficient mice. BV2 is applicable to research related to Duchenne muscular dystrophy and muscle atrophy .
|
-
- HY-P10350
-
|
|
NF-κB
|
Neurological Disease
Inflammation/Immunology
|
|
PapRIV is an agonist of BV-2 microglial cells, capable of activating microglial cells through an NF-κB-dependent pathway. PapRIV induces the expression of pro-inflammatory cytokines such as IL-6 and TNFα and increases the production of reactive oxygen species (ROS). PapRIV can cross the blood-brain barrier .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-W050044
-
-
-
- HY-W019670
-
-
-
- HY-N2259
-
-
-
- HY-129440
-
|
|
Structural Classification
Classification of Application Fields
Carthamus tinctorius L.
Phenols
Polyphenols
Plants
Compositae
Inflammation/Immunology
Disease Research Fields
Source Classification
|
NF-κB
Toll-like Receptor (TLR)
p38 MAPK
NO Synthase
COX
ERK
Caspase
PDGFR
MyD88
Reactive Oxygen Species (ROS)
Apoptosis
|
|
N-(p-Coumaroyl) Serotonin is an orally active polyphenol found in safflower seeds with potent anti-inflammatory, antioxidant, and antitumor activities. N-(p-Coumaroyl) Serotonin suppresses NF‑κB, TLR4/MyD88 and MAPK signaling, activates NQO1/HO‑1 pathways, and inhibits pro‑inflammatory cytokines, iNOS and COX‑2 and ROS production. N-(p-Coumaroyl) Serotonin induces S‑phase arrest and apoptosis in glioblastoma cells, reduces atherosclerotic lesions, and alleviates renal and vascular injuries. N-(p-Coumaroyl) Serotonin acts as a vasodilator, regulates calcium dynamics. N-(p-Coumaroyl) Serotonin can be used for the research of neurodegenerative diseases, atherosclerosis, glioblastoma, and acute renal failure [2] .
|
-
-
- HY-N0506
-
-
-
- HY-N0911
-
-
-
- HY-N5025
-
-
-
- HY-N10424
-
-
-
- HY-N8371
-
-
-
- HY-126066
-
-
-
- HY-116474
-
|
|
Infection
Alkaloids
Structural Classification
Monophenols
Microorganisms
Classification of Application Fields
Phenols
Quinoline Alkaloids
Disease Research Fields
Source Classification
|
ERK
JNK
MMP
p38 MAPK
STAT
Fungal
Bacterial
NO Synthase
PGE synthase
NF-κB
Wnt
β-catenin
|
|
Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis [2] .
|
-
-
- HY-N6893
-
|
|
Phyllodium pulchellum (L.) Desv.
Structural Classification
Classification of Application Fields
Ketones, Aldehydes, Acids
Plants
Compositae
Inflammation/Immunology
Disease Research Fields
Piptanthus nepalensis (Hook.) D. Don
Source Classification
|
NF-κB
NOD-like Receptor (NLR)
Apoptosis
Autophagy
|
Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the NACHT domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE2) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia [2] .
|
-
-
- HY-121811
-
|
Lanceolatin C
|
Structural Classification
Pongamia pinnata (L.) Pierre
Leguminosae
Ketones, Aldehydes, Acids
Derris trifoliata Lour.
Plants
Source Classification
|
Glycosidase
Phosphatase
Interleukin Related
TNF Receptor
COX
Beclin1
GLUT
FAK
Akt
mTOR
p38 MAPK
Keap1-Nrf2
Apoptosis
Amyloid-β
Tau Protein
Autophagy
|
|
Pongamol is an orally active flavonoid with an IC50 of 75 μM and a Ki of 58 μM against PTPase-1B, and an IC50 of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, TNF‑α, COX‑2 and iNOS in cells, reverses the nuclear translocation of NF‑κB, and upregulates the levels of Beclin 1 and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol alleviates oxidative stress, neuroinflammation, Aβ deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia [2] .
|
-
-
- HY-W019670R
-
-
-
- HY-N0761A
-
-
-
- HY-12688
-
|
|
Structural Classification
Neurological Disease
Classification of Application Fields
Ketones, Aldehydes, Acids
Endogenous metabolite
Disease Research Fields
Source Classification
|
Mitochondrial Metabolism
Reactive Oxygen Species (ROS)
Amyloid-β
|
|
Succinyl phosphonate is a α-Ketoglutarate Dehydrogenase Complex (KGDHC) modulator with neuroprotective activity. Succinyl phosphonate protects this complex, reduces cellular succinyl-CoA concentration, downregulates protein succinylation levels, and inhibits the activity of the α-ketoglutarate dehydrogenase complex. Succinyl phosphonate corrects hypoxic or ethanol-induced behavioral impairments, modulates exploratory behavior and emotional stress responses, and improves hypoxia tolerance. Succinyl phosphonate reduces glutamate excitotoxicity, restores the activity of the α-ketoglutarate dehydrogenase complex, reverses the changes in glutamate dehydrogenase and glutamine synthetase activities induced by β-amyloid (Amyloid-β), modulates cognitive function, and prevents β-amyloid-induced neuronal damage. Succinyl phosphonate improves microglial senescence, alleviates neuroinflammation, reactive oxygen species (ROS) production, lipid peroxidation, and the expression of proinflammatory cytokines. Succinyl phosphonate can be used in the research of Alzheimer's disease, aging-related neuroinflammation, and Parkinson's disease [2] .
|
-
-
- HY-N8631
-
-
-
- HY-N10782
-
-
-
- HY-N2439
-
-
-
- HY-N11657
-
-
-
- HY-138050
-
-
-
- HY-N2259R
-
-
-
- HY-N4190
-
-
-
- HY-N9164
-
-
-
- HY-N8090
-
|
|
Triterpenes
Microorganisms
Classification of Application Fields
Terpenoids
Inflammation/Immunology
Disease Research Fields
Source Classification
|
NO Synthase
|
|
(3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid, a lanostane triterpenoids, exhibits obvious NO inhibitory activity on n LPS-induced BV-2 microglia cells with an IC50 of 9.55 uM. (3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid has anti-inflammatory activities .
|
-
-
- HY-N10386
-
-
-
- HY-N2968
-
-
-
- HY-N15566
-
-
-
- HY-N10066
-
-
-
- HY-N3760
-
-
-
- HY-N11945
-
-
-
- HY-N10119
-
-
-
- HY-N11943
-
-
-
- HY-W095499
-
-
-
- HY-N12525
-
-
-
- HY-N10275
-
-
-
- HY-N0859B
-
-
-
- HY-N12527
-
-
-
- HY-119465
-
|
|
Microorganisms
Antibiotics
Other Antibiotics
Source Classification
|
Fungal
|
|
Restricticin is a compound obtained from marine fungi, whose structure contains alkene, tetrahydropyran ring and glycine ester functional groups, and has anti-neuroinflammatory effects in lipopolysaccharide-induced BV-2 microglia by inhibiting the production of proinflammatory mediators.
|
-
-
- HY-N3473
-
-
-
- HY-N9675
-
-
-
- HY-N7018
-
-
-
- HY-N15570
-
|
|
Microorganisms
Phenols
Polyphenols
Source Classification
|
Interleukin Related
TNF Receptor
|
|
2-O-Methylatromentin is an anti-neuroinflammatory agent. 2-O-Methylatromentin shows inhibitory activity on the production of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β in Lipopolysaccharides (HY-D1056) (LPS) -induced BV-2 microglial cells. 2-O-Methylatromentin can be used for the study of neuroinflammatory related diseases .
|
-
-
- HY-N8936
-
|
|
Terpenoids
Sesquiterpenes
Nardostachys jatamansi (D. Don) DC.
Plants
Valerianaceae
Source Classification
|
Others
|
|
Narchinol B (Compound 4) is a sesquiter penoid
compound. Narchinol B has anti-inflammatory effects. Narchinol B works by
inhibiting proinflammatory mediators, including prostaglandin E2 (PGE2),
inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) proteins,
as well as proinflammatory cytokines, such as interleukin-1b, IL-6, and tumor
necrosis factor-α (TNF-α). Narchinol B significantly inhibits LPS-induced
overproduction of NO in BV2 cells (IC50=2.43 μM)
.
|
-
-
- HY-N13701
-
|
|
Triterpenes
Microorganisms
Terpenoids
Source Classification
|
NO Synthase
|
|
3β,7β,15α-Trihydroxy-4-(hydroxymethyl)-11,23-dioxo-lanost-8-en-26-oic acid is a triterpene compound that can be found in Ganoderma lucidum, and it inhibits nitric oxide (NO) production in BV-2 microglial cells induced by lipopolysaccharide (LPS, HY-D1056), with an IC50 of 4.15 μM .
|
-
-
- HY-N0894A
-
-
-
- HY-N13706
-
|
|
Triterpenes
Microorganisms
Terpenoids
Source Classification
|
NO Synthase
|
|
3β,15α-Dihydroxy-7,11,23-trioxo-lanost-8-dien-26-oic acid is a triterpene compound that can be found in Ganoderma lucidum, and it inhibits nitric oxide (NO) production in BV-2 microglial cells induced by lipopolysaccharide (LPS, HY-D1056), with an IC50 of 6.50 μM, making it a potential candidate for anti-inflammatory research .
|
-
-
- HY-N16626
-
-
-
- HY-N3814
-
-
-
- HY-N0506R
-
-
- HY-W050044R
-
-
- HY-N15564
-
|
|
Microorganisms
Phenols
Polyphenols
Source Classification
|
Drug Derivative
|
|
Theleganbanin B is a p-terphenyl derivative found in the Thelephora ganbajun. Theleganbanin B inhibits TNF-α, IL-6, and IL-1β production in LPS-induced BV-2 microglial cells. Theleganbanin B inhibits the phosphorylation of JAK2/STAT3. Theleganbanin B is promising for research of neurodegenerative diseases .
|
-
- HY-N10274
-
-
- HY-N13831
-
-
- HY-N10458
-
|
|
Sesquiterpenes
|
NF-κB
|
|
Asperbisabolane L, a sesquiterpenoid, exerts the anti-inflammatory activity by inhibiting the NF-κB-activated pathway. Asperbisabolane L inhibits the translocation of NF-κB from cytoplasm to the nucleus. Asperbisabolane L also inhibits NO production in LPS-activated BV-2 microglia cells .
|
-
- HY-N19854
-
-
- HY-N13729
-
-
- HY-N15565
-
-
- HY-N1263
-
-
- HY-131616
-
-
- HY-N18031
-
-
- HY-N18012
-
-
- HY-N17383
-
|
|
Structural Classification
Natural Products
Umbelliferae
Plants
Echinacea angustifolia DC.
Source Classification
|
Toll-like Receptor (TLR)
NF-κB
Collagen
Interleukin Related
Cadherin
NOD-like Receptor (NLR)
TGF-β Receptor
FXR
Apoptosis
|
|
Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease [2] .
|
-
- HY-N6998A
-
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-172451
-
|
|
|
Alkynes
|
|
MC4762 is an inhibitor of NOX2 and MAOB, with IC50 values of 0.155 μM and 0.182 μM, respectively. MC4762 has anti-inflammatory activity, can inhibit the production of ROS, and downregulate the expression of pro-inflammatory cytokines iNOS, IL-1β, and IL-6 .
|
| Cat. No. |
Product Name |
|
Classification |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
